JP2018522879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522879A5 JP2018522879A5 JP2017568230A JP2017568230A JP2018522879A5 JP 2018522879 A5 JP2018522879 A5 JP 2018522879A5 JP 2017568230 A JP2017568230 A JP 2017568230A JP 2017568230 A JP2017568230 A JP 2017568230A JP 2018522879 A5 JP2018522879 A5 JP 2018522879A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- halogen
- substituted
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 125000005842 heteroatom Chemical group 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 102000001301 EGF receptor Human genes 0.000 claims description 8
- 108060006698 EGF receptor Proteins 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- -1 4-fluoro-2-hydroxyphenyl Chemical group 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 0 CCC(C)(*I)C(*)C(C)(CC)N(*)C(C(*)(*)C*(C)*)=O Chemical compound CCC(C)(*I)C(*)C(C)(CC)N(*)C(C(*)(*)C*(C)*)=O 0.000 description 1
- GHMJQGDZGLPNID-JOCHJYFZSA-N CN(C)CCCCNC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O Chemical compound CN(C)CCCCNC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O GHMJQGDZGLPNID-JOCHJYFZSA-N 0.000 description 1
- WTIFBTDPLZLHIE-HXUWFJFHSA-N CN(C)CCNC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O Chemical compound CN(C)CCNC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O WTIFBTDPLZLHIE-HXUWFJFHSA-N 0.000 description 1
- KRIPJXKSMZJIBQ-QHCPKHFHSA-N N#Cc(ccc(-c1cc(C(N(C2)[C@H](C(Nc3ncc[s]3)=O)c3ccccc3)=O)c2cc1)c1)c1F Chemical compound N#Cc(ccc(-c1cc(C(N(C2)[C@H](C(Nc3ncc[s]3)=O)c3ccccc3)=O)c2cc1)c1)c1F KRIPJXKSMZJIBQ-QHCPKHFHSA-N 0.000 description 1
- ABAFOMPQGIJEJY-MRXNPFEDSA-N NC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O Chemical compound NC(c1c[s]c(NC([C@@H](c2ccccc2)N(Cc2c3cccc2)C3=O)=O)n1)=O ABAFOMPQGIJEJY-MRXNPFEDSA-N 0.000 description 1
- XIUJTXJZLIPLAN-MRXNPFEDSA-N O=C([C@@H](c1ccccc1)N(Cc1c2cccc1)C2=O)Nc1ncc[o]1 Chemical compound O=C([C@@H](c1ccccc1)N(Cc1c2cccc1)C2=O)Nc1ncc[o]1 XIUJTXJZLIPLAN-MRXNPFEDSA-N 0.000 description 1
- QXFMIOWJOJZIRH-SANMLTNESA-N O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c(cc1)ccc1N1CCNCC1)C2=O)Nc1ncc[s]1 Chemical compound O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c(cc1)ccc1N1CCNCC1)C2=O)Nc1ncc[s]1 QXFMIOWJOJZIRH-SANMLTNESA-N 0.000 description 1
- BNUQRXMZYMIFSE-QFIPXVFZSA-N O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c(cccc1)c1F)C2=O)Nc1ncc[s]1 Chemical compound O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c(cccc1)c1F)C2=O)Nc1ncc[s]1 BNUQRXMZYMIFSE-QFIPXVFZSA-N 0.000 description 1
- GRSCCESMUDSCTN-DEOSSOPVSA-N O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c1ccc3[nH]ccc3c1)C2=O)Nc1ncc[s]1 Chemical compound O=C([C@H](c1ccccc1)N(Cc(cc1)c2cc1-c1ccc3[nH]ccc3c1)C2=O)Nc1ncc[s]1 GRSCCESMUDSCTN-DEOSSOPVSA-N 0.000 description 1
- XIUJTXJZLIPLAN-INIZCTEOSA-N O=C([C@H](c1ccccc1)N(Cc1c2cccc1)C2=O)Nc1ncc[o]1 Chemical compound O=C([C@H](c1ccccc1)N(Cc1c2cccc1)C2=O)Nc1ncc[o]1 XIUJTXJZLIPLAN-INIZCTEOSA-N 0.000 description 1
- GMWYJNZPGWLIDU-GEPVFLLWSA-N OC(c1c(C2)cccc1)N2[C@@H](C(Nc1nc(C(NCCCN2CCOCC2)=O)c[s]1)=O)c1ccccc1 Chemical compound OC(c1c(C2)cccc1)N2[C@@H](C(Nc1nc(C(NCCCN2CCOCC2)=O)c[s]1)=O)c1ccccc1 GMWYJNZPGWLIDU-GEPVFLLWSA-N 0.000 description 1
- FBOJEGDMSRTUMT-KPMSDPLLSA-N OCC(CNC(c(cc(cc1)Br)c1N[C@@H](C(Nc1ncc[s]1)=O)c1ccccc1)=O)O Chemical compound OCC(CNC(c(cc(cc1)Br)c1N[C@@H](C(Nc1ncc[s]1)=O)c1ccccc1)=O)O FBOJEGDMSRTUMT-KPMSDPLLSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- FICIRGPWTGYDRZ-KPMSDPLLSA-N [O-][N+](c(c(C(NCC(CO)O)=O)c1)ccc1N[C@@H](C(Nc1ncc[s]1)=O)c1ccccc1)=O Chemical compound [O-][N+](c(c(C(NCC(CO)O)=O)c1)ccc1N[C@@H](C(Nc1ncc[s]1)=O)c1ccccc1)=O FICIRGPWTGYDRZ-KPMSDPLLSA-N 0.000 description 1
- AQLNCSCONZBQLS-XMMPIXPASA-N [O-][N+](c1cc([C@H](C(Nc2ncc[s]2)=O)N(Cc(cc2)c3cc2-c2ccc4[nH]ccc4c2)C3=O)ccc1)=O Chemical compound [O-][N+](c1cc([C@H](C(Nc2ncc[s]2)=O)N(Cc(cc2)c3cc2-c2ccc4[nH]ccc4c2)C3=O)ccc1)=O AQLNCSCONZBQLS-XMMPIXPASA-N 0.000 description 1
- WOUMAWTZNHUTOU-MRXNPFEDSA-N [O-][N+](c1cc([C@H](C(Nc2ncc[s]2)=O)N(Cc2c3cccc2)C3=O)ccc1)=O Chemical compound [O-][N+](c1cc([C@H](C(Nc2ncc[s]2)=O)N(Cc2c3cccc2)C3=O)ccc1)=O WOUMAWTZNHUTOU-MRXNPFEDSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186563P | 2015-06-30 | 2015-06-30 | |
| US62/186,563 | 2015-06-30 | ||
| US201562259895P | 2015-11-25 | 2015-11-25 | |
| US62/259,895 | 2015-11-25 | ||
| PCT/US2016/040421 WO2017004383A1 (en) | 2015-06-30 | 2016-06-30 | Inhibitors of egfr and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522879A JP2018522879A (ja) | 2018-08-16 |
| JP2018522879A5 true JP2018522879A5 (enExample) | 2019-07-25 |
| JP6845165B2 JP6845165B2 (ja) | 2021-03-17 |
Family
ID=57609152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568230A Active JP6845165B2 (ja) | 2015-06-30 | 2016-06-30 | Ｅｇｆｒ阻害剤およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10385019B2 (enExample) |
| EP (1) | EP3317273B1 (enExample) |
| JP (1) | JP6845165B2 (enExample) |
| CN (1) | CN107849034B (enExample) |
| AU (1) | AU2016288204B2 (enExample) |
| CA (1) | CA2987914C (enExample) |
| HK (1) | HK1252693A1 (enExample) |
| WO (1) | WO2017004383A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989326T3 (es) * | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| JP6911019B2 (ja) * | 2016-05-17 | 2021-07-28 | 公益財団法人がん研究会 | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 |
| TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| KR20190101406A (ko) | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
| CR20190542A (es) * | 2017-06-02 | 2020-01-14 | Hoffmann La Roche | Compuestos |
| WO2019001307A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市塔吉瑞生物医药有限公司 | 一种酰胺类化合物及包含该化合物的组合物及其用途 |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| TW201945357A (zh) * | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| EP3755330A4 (en) * | 2018-02-20 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND THEIR METHODS OF USE |
| JP7313364B2 (ja) | 2018-02-21 | 2023-07-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 |
| WO2019183523A1 (en) * | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl) |
| CN110372666B (zh) * | 2018-04-13 | 2022-11-08 | 华东理工大学 | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 |
| BR112020026450A2 (pt) * | 2018-06-29 | 2021-03-23 | F. Hoffmann-La Roche Ag | Compostos de fórmula i |
| CN108570044A (zh) * | 2018-07-02 | 2018-09-25 | 秦继伟 | 一种酰胺类化合物及其合成方法和治疗癌症的用途 |
| CN108690013A (zh) * | 2018-07-02 | 2018-10-23 | 秦继伟 | 苯并[d]噻唑衍生物及其作为EGFR抑制剂在癌症治疗中的应用 |
| CN108912115A (zh) * | 2018-07-02 | 2018-11-30 | 秦继伟 | 一种用于治疗肺癌的egfr酪氨酸激酶抑制剂 |
| CN108892664A (zh) * | 2018-07-02 | 2018-11-27 | 秦继伟 | 一种酰胺类化合物及其合成方法和治疗癌症的用途 |
| UA129328C2 (uk) | 2019-06-21 | 2025-03-19 | Ф. Хоффманн-Ля Рош Аг | Інгібітор egfr для лікування раку |
| CA3144402C (en) * | 2019-06-21 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Allosteric egfr inhibitors and methods of use thereof |
| MA56507A (fr) * | 2019-06-21 | 2022-04-27 | Hoffmann La Roche | Nouveaux inhibiteurs d'egfr |
| WO2020254544A1 (en) * | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | New egfr inhibitors |
| KR20220052904A (ko) * | 2019-06-21 | 2022-04-28 | 다나-파버 캔서 인스티튜트 인크. | 알로스테릭 egfr 억제제 및 이의 사용 방법 |
| JP7590996B2 (ja) | 2019-06-24 | 2024-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体 |
| CN120398836A (zh) | 2019-11-11 | 2025-08-01 | 达纳-法伯癌症研究所股份有限公司 | 变构egfr抑制剂及其使用方法 |
| KR102267662B1 (ko) * | 2019-11-19 | 2021-06-22 | 한국화학연구원 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| AR120800A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |
| MX2022007659A (es) * | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| AR120799A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| MX2022015739A (es) * | 2020-06-09 | 2023-03-23 | Dana Farber Cancer Inst Inc | Inhibidores alostericos de egfr y metodos de uso de estos. |
| CN111592535B (zh) * | 2020-06-22 | 2021-07-20 | 通化师范学院 | 一种抗egfr突变的抑制剂eai045的制备方法 |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| JP2023551769A (ja) | 2020-12-01 | 2023-12-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| EP4255908A1 (en) * | 2020-12-01 | 2023-10-11 | F. Hoffmann-La Roche AG | New indazole acetylene derivatives |
| US20240018154A1 (en) * | 2020-12-01 | 2024-01-18 | Hoffmann-La Roche Inc. | New indazole derivatives |
| KR102733257B1 (ko) * | 2021-05-17 | 2024-11-26 | 에이치케이이노엔 주식회사 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| AR127064A1 (es) | 2021-09-15 | 2023-12-13 | Hua Medicine Shanghai Ltd | Prodroga de derivados de pirrolidona como activador de glucoquinasa |
| CN117126142B (zh) * | 2023-08-30 | 2026-02-10 | 遵义医科大学珠海校区 | 杂环类egfr突变抑制剂及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2374236C2 (ru) * | 2001-12-21 | 2009-11-27 | Ново Нордиск А/С | Амидные производные в качестве активаторов gk |
| EP1594845A4 (en) * | 2003-02-11 | 2008-05-21 | Bristol Myers Squibb Co | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS |
| GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| DE602006011752D1 (de) * | 2005-06-24 | 2010-03-04 | Bristol Myers Squibb Co | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US8034822B2 (en) * | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| US8008332B2 (en) * | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
| PT2129654E (pt) * | 2007-02-09 | 2014-09-04 | Metabasis Therapeutics Inc | Antagonistas do receptor de glucagina |
| BRPI0820722A2 (pt) | 2007-12-20 | 2015-06-16 | Novartis Ag | Derivados de tiazol usados como inibidores de pi 3 cinases |
| JP5937353B2 (ja) * | 2008-08-19 | 2016-06-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | 冷感−メントール受容体拮抗剤 |
| AU2009298877A1 (en) | 2008-09-23 | 2010-04-08 | Georgetown University | Viral and fungal inhibitors |
| US20120142705A1 (en) * | 2010-12-06 | 2012-06-07 | Robert Francis Kester | Isatin and oxindole compounds |
| US9464065B2 (en) * | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| WO2014106800A2 (en) * | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
-
2016
- 2016-06-30 CA CA2987914A patent/CA2987914C/en active Active
- 2016-06-30 HK HK18112001.2A patent/HK1252693A1/zh unknown
- 2016-06-30 JP JP2017568230A patent/JP6845165B2/ja active Active
- 2016-06-30 CN CN201680043974.5A patent/CN107849034B/zh active Active
- 2016-06-30 WO PCT/US2016/040421 patent/WO2017004383A1/en not_active Ceased
- 2016-06-30 US US15/580,088 patent/US10385019B2/en active Active
- 2016-06-30 EP EP16818796.1A patent/EP3317273B1/en active Active
- 2016-06-30 AU AU2016288204A patent/AU2016288204B2/en not_active Ceased
-
2019
- 2019-06-13 US US16/440,803 patent/US10836722B2/en active Active
-
2020
- 2020-09-28 US US17/035,164 patent/US20210094913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522879A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| JP2019510810A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| RU2018128318A (ru) | Селективные ингибиторы эстрогеновых рецепторов и их применение | |
| JP2016537366A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2018128334A (ru) | Ингибиторы индоламин-2,3-диоксигеназы (ido) | |
| JP2016526540A5 (enExample) | ||
| SI2922844T1 (en) | N-PYROLIDINYL, N'-PYRAZOLYL-WATER, TIOUREE, GVANIDINE AND CYANOGVANIDINE COMPOUNDS AS THE BLOOD KINASE INHIBITORS | |
| JP2016518437A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2015514806A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2016537369A5 (enExample) | ||
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2010504346A5 (enExample) |